• About
  • Team
  • Portfolio
  • News
  • Contact
September 26, 2018 in Uncategorized by Christophe Guichard 0 Comments

GeNeuro Announces Positive 6-Month Phase IIa Data for GNbAC1 in Adults with Type 1 Diabetes

Geneva, Switzerland, 26 September 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced that its Pha ...

September 26, 2018 in Uncategorized by Christophe Guichard 0 Comments

Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 for Primary Biliary Cholangitis

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today the completion of enrollment in its Phase 2 trial of GKT831 in patients with P ...

September 18, 2018 in Uncategorized by Christophe Guichard 0 Comments

GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier

Paris, France and Geneva, Switzerland, September 18, 2018 – 07:30am CEST – Servier and GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that GeNeuro has regained worldwide rights ex US and Japan to its lead ...

September 3, 2018 in Uncategorized by Christophe Guichard 0 Comments

Genkyotex Announces Positive Outcome from the Second Independent SMB Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GK ...

Eclosion

Campus Biotech
Innovation Park
Bâtiment F2
Av. Sécheron 15
1201 Geneva
Suisse

Tel: +41 (0)22 544 29 34

    Logo
    Eclosion Ventures © 2021 | Crédits